Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nuvilex skyrocketed to .62 because of all the traders that jumped on the stock and also created short covering...it went up too far too fast...so it corrected itself...now is the time that Nuvilex is going to start climbing on its own merits...you will always have the short traders but the bashing is not going to work anymore...the milestones are happening...we all know that...all of us...so hang on for the ride up and be ready to add to your position with the dips if you want more...
bull
the upcoming study in August is performed on mice...
bull
Nuvilex Provides Shareholder Update on Milestone Accomplishments
Nuvilex Provides Shareholder Update on Milestone Accomplishments
SILVER SPRING, Md., July 14, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, today issued the following shareholder update letter from Kenneth L. Waggoner, CEO and President.
Dear Nuvilex Shareholders,
First and foremost, on behalf of the entire Nuvilex Management Team we wish to thank you for your continued support. We are pleased to provide this update on the tremendous progress we are making at Nuvilex and share with you our vision for the future of Nuvilex. Since being named as CEO in late November, 2013, our entire team has worked diligently to ensure Nuvilex remains focused and dedicated to becoming a significant player in the biotech industry. The past seven months have been monumental for the growth of Nuvilex as a biotechnology company while, at the same time, we implemented plans to create substantial shareholder value. We expect the next six months to mark a major turning point in our growth, as we embark upon critical phase 2b trials and groundbreaking preclinical studies with our incredible technology and treatments. To be certain, our brightest days lie ahead.
Nuvilex's accomplishments since the first of this year include:
Capitalization and Funding for Future Growth
-- Nuvilex's financial position has become the strongest in the Company's
history. Nuvilex is virtually debt-free and has access to all of the
necessary capital it requires to meet both its short-term and long-term
monetary commitments. In addition, Nuvilex has established credibility
with accredited and institutional investors who have expressed a desire
to fund Nuvilex's expansion plans under reasonable terms.
-- Nuvilex has secured a traditional investment banking relationship with
Chardan Capital Markets, a multi-national firm with offices located in
New York, Los Angeles and Beijing. Chardan will be acting as the
Company's placement agent for the resale of shares that will be sold
through Nuvilex's S-3 Registration Statement to be filed with the
Securities and Exchange Commission. The sale or placement of any shares
sold following an effective S-3 Registration Statement will be conducted
so as to preserve shareholder value as its top priority.
Multifaceted Approach to Treatment Opportunities with Cell-in-a-Box(R)
-- Nuvilex has completed the necessary preliminary steps to commence a Phase
2b clinical trial of its pancreatic cancer treatment that it expects to
begin in Q1 2015. Nuvilex's treatment (Cell-in-a-Box(R) plus ifosfamide)
will be compared "head-to-head" with the best available therapy
(currently Abraxane(R) plus gemcitabine) for advanced, inoperable
pancreatic cancer. The trial will be conducted in Australia where one of
that country's leading clinical research organizations (CRO), Clinical
Network Services, has been contracted by Nuvilex to conduct all aspects
of the trial. Dr. Matthias Löhr, one of Europe's leading
oncologists/gastroenterologists with extensive experience in treating
pancreatic cancer and the principal investigator for the previous
successful Phase 1/2 trials using the Cell-in-a-Box(R)/ifosfamide
combination in pancreatic cancer, has agreed to oversee the Phase 2b
trial in Australia.
-- Nuvilex has also made significant developments towards conducting
preclinical and clinical studies related to the "quality of life" of
patients with advanced, inoperable pancreatic cancer. Nuvilex expects one
of the preclinical studies to begin in early August, 2014, as recently
announced. In particular, these studies will help determine if Nuvilex's
pancreatic cancer treatment can have beneficial effects on two major
symptoms that accompany advanced pancreatic cancer, namely the unbearable
and often untreatable pain and the accumulation of malignant ascites
fluid in the abdomen. Nuvilex and TD2, America's "Premier Oncology CRO,"
are expecting the arrival of encapsulated live cells capable of
converting the ifosfamide into its cancer-killing form at the TD2
facilities in Scottsdale, Arizona, the first week of August. TD2 is
scheduled to begin these studies shortly after the arrival of the
encapsulated cells. The initial preclinical studies will concern the
accumulation of ascites fluid and, if successful, will lead to clinical
trials.
-- Meetings have been held between Nuvilex's principal officers and
scientists and principals from some of the major universities in Europe
concerning the use of the Cell-in-a-Box(R) technology in developing a
treatment for insulin-dependent diabetes. Scientists at one of these
institutions have developed unique transgenic animal models for
insulin-dependent diabetes. Nuvilex has initiated negotiations for their
use in its studies of this disease. In addition, scientists at an
Australian university have developed a human cell line that secretes
increasing amounts of insulin in response to increasing levels of glucose
in their surroundings. If the results of preclinical tests on these cells
are positive, Nuvilex will finalize negotiations to acquire this cell
line for use with the Cell-in-a-Box(R) technology as a first step in
developing its treatment for diabetes.
-- Nuvilex's work in the medical marijuana field continues under the
direction of Dr. Mark L. Rabe, Chairman of the Scientific Advisory Board
of Nuvilex's subsidiary, Medical Marijuana Sciences, Inc. (MMS). The work
in this area is initially directed to developing treatments for two of
the deadliest and hard-to-treat forms of cancer -- brain cancer and
pancreatic cancer - that combine Cell-in-a-Box(R) technology with
constituents of Cannabis known as cannabinoids. Initial studies have
already begun under the leadership of Dr. Richard M. Hyslop at the
University of Northern Colorado to develop a cell line that can be
encapsulated using the Cell-in-a-Box(R) technology and that then can be
used to convert certain cannabinoids from cannabis into cancer-killing
drugs. The results of those studies should be received by the end of this
year. Dr. Hyslop is also a member of MMS' Scientific Advisory Board.
In February, Dr. Garret L. Yount, a Research Scientist at the California Pacific Medical Center Research Institute in San Francisco, was appointed to MMS' SAB. Dr. Yount and his colleagues have demonstrated, in preclinical studies, the anticancer activity of cannabinoids against brain cancer cells in the laboratory and against brain cancer in animal models. Dr. Yount's preclinical expertise will interact closely with that of Dr. Hyslop. As Dr. Hyslop performs the early studies to develop Cell-in-a-Box(R) /cannabinoid combinations, Dr. Yount will have the expertise to test these combinations in preclinical model systems.
Finally, Dr. Brian Salmons, co-inventor and co-developer of the Cell-in-a-Box(R) technology, has accepted a position on MMS' SAB. Dr. Salmons' contributions to the development of Cell-in-a-Box(R) /cannabinoid contributions that may be effective against brain and pancreatic cancers should prove to be invaluable.
The second half of 2014 should prove to be a very dynamic time for Nuvilex. We will be working diligently on the steps required for CNS to conduct our Phase 2b clinical trial in advanced pancreatic cancer in Australia and pursuing Orphan Drug status for our pancreatic cancer treatment in the U.S., the EU and Australia. We anticipate preparing for preclinical studies utilizing our Cell-in-a-Box(R) technology for diabetes. We will be working with TD2 on the preclinical studies in the U.S. related to symptoms experienced by patients suffering from advanced pancreatic cancer and making preparations for the subsequent clinical trials that will be conducted by TD2 in the U.S.
In closing, we believe that the Cell-in-a-Box(R) technology is one of the most diverse platform technologies to emerge in the medical field over the past decade. We trust that our efforts to date in pancreatic cancer and diabetes will begin to validate this belief and potentially provide physicians and patients with new solutions to these serious and deadly diseases.
Sincerely,
Kenneth L. Waggoner
http://online.wsj.com/article/PR-CO-20140714-905001.html
bull
when they said 1st Quarter of 2015 they are referring to the 1st quarter of the year 2015 January to March...what don't you understand about that...why don't you read the other responses to this ridiculous conversation or go do your own DD...I'm done with this conversation
bull
I never said that Nuvilex's 1st Q was in Jan...
bull
a year has 4 quarters...I never said the trials would start in Nuvilex's 1st Quarter...I said the trials would start in the first quarter of 2015 which is Jan-Mar and is in 6 months...I emailed Marlin and he responded with he believes the trials are starting between Jan-Mar...so I was right...how much clearer do you need the response to be...
bull
I beg to differ...I emailed the company and the response from Marlin was he believes it to be the Jan-Mar time frame like I said...so you need to get your facts straight before you go off on someone...
bull
Does that really matter...they gave a time frame of the cells being here in the U.S. the first week of August...when everything else is prepped with the mice they will commence...
bull
first Quarter of next year...I said nothing about Nuvilex's first quarter...so you are the one that has your facts wrong...and I am sure all the long investors here know exactly what I was talking about...
bull
3 Reason to OWN Nuvilex right here right NOW
Pre-clinical study to start 1st of August with Dr. Von Hoff...
Clinical Phase I to start 1st Q with Dr. Von Hoff...
and last and most important Late Phase 2b (mini phase 3) to start 1st Q...6 months from now...
bull
you can find that information on the TD2 website where they have Nuvilex's PR posted with Dr. Von Hoff's quote...but thanks for posting for us anyway...
bull
Nuvilex Scheduled to Begin Preclinical Studies in Early August
do you know who I think is going to become one of the most important factors after Dr. Von Hoff's trial...The Pancreatic Cancer Research Team (PCRT).....40 clinics worldwide, focused on the rapid development of novel therapeutics for pancreatic cancer....premiere resource for biotech and pharmaceutical companies looking to develop new agents for patients with pancreas cancer...dedicated to rapidly translating research discoveries into new treatments and supportive care....think about it...what they could accomplish in a short amount of time..
bull
Austrianova Singapore is GMP compliant..
bull
Strategic Partnership for Diabetes will be Next
I think more came out of that last meeting than we know...all coming to fruition at once...Late Stage 2b...TD2 trials and Diabetes partnership is next...
bull
I agree...the reason I am bringing up the diabetes is because if you read pr's about Nuvilex and what good results with diabetes will do to this stock ...there is big excitement around that because unlike pancreatic cancer where they are going for better quality of life...with diabetes they can actually make it so a patient will not have to take shots...the talk is they can go 6 months or so before any treatment...Nuvilex teaming up with Juvenile Diabetes Research Foundation which is based in the US is huge...and SG Austria already had connections with world renown doctors in the EU on diabetes...
we will hear something on diabetes soon I think..
bull
Everything is coming to fruition....Austrianova already had connections for diabetes...maybe that is why the talks went so well when they were here...
bull
don't be surprised if we hear of a strategic partnership soon for child diabetes...
bull
we are only 6 months out until Late Stage 2b and TD2 both start their trials...getting close guys...
bull
well now you see what this little Nuvilex can do in a matter of minutes....
bull
no they don't always fill the gap...especially bios...I have plenty of stocks with gaps...Nuvilex experienced a slow very low volume sell off before the trials start...that is all...so the shorts made money...so what...so will all the longs that hold Nuvilex...
bull
nice find
bull
Thank you for re-posting the news on Nuvilex
bull
200,000 shares of Nuvilex would not even move the stock pps...
bull
Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market
NEW YORK, NY, Jul 07, 2014 (Marketwired via COMTEX) -- Nuvilex, Inc. (otcqb:NVLX) announced last week that its executives recently met with the company's "global development partners" at the 2014 BIO International Convention in San Diego. One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex's plans for treating diabetes. This, of course, begs the question -- is Nuvilex in line for a partnership to bring its diabetes treatment to market?
Currently the JDRF is funding more than 50 human clinical trials worldwide, and with the number of diabetes cases predicted to climb to 592 million by 2035 if "urgent action" isn't taken, it's easy to understand why so many biopharmaceutical firms are making the disease a priority. According to the International Diabetes Federation, the market for diabetes medicines alone is expected to reach $114 billion by 2018.
While the focus for investors has been on Nuvilex's pancreatic cancer treatment and its Phase 2b clinical trial and preclinical studies, the company is clearly further along with plans to get its diabetes treatment using the Cell-in-a-Box(R) technology it owns the worldwide rights to develop and market into the clinic than most realize.
The company stated last week that it is planning additional meetings with the JDRF "in the near future to explore ways the company and the Foundation may collaborate." Nuvilex has also met with a representative of the university from which the company plans "to license the human insulin-producing cell line that will be used to develop a treatment for insulin-dependent diabetes."
For those unfamiliar with Nuvilex's diabetes treatment, it may be of interest to the JDRF because a "proof of principle" study using the treatment essentially created an "artificial pancreas." It was this study that led Nuvilex execs to purchase the worldwide rights to the treatment.
In the study, cells that produce insulin were encapsulated and transplanted into diabetic animals. The diabetic animals had much higher than normal levels of glucose in their bloodstream and had a difficult time controlling their glucose levels, just as humans with diabetes do.
In the animals provided with encapsulated cells, their blood glucose levels normalized and remained stable for the duration of one six-month study, indicating the encapsulated cells produced insulin in response to their higher than normal blood glucose levels. The cellulose-based capsules seem to have prevented the encapsulated cells inside from being attacked by the diabetic animals' immune systems, even in the absence of immunosuppressive drugs.
Therefore, the encapsulated cells appear to have acted as an artificial or replacement pancreas, and if Nuvilex can replicate this study, the JDRF likely won't be the only collaboration the company will be sitting down with in private meetings.
http://www.marketwatch.com/story/nuvilex-eyeing-partnership-for-its-share-of-future-114-billion-diabetes-market-2014-07-07
bull
that interview was the first time I heard when the TD2 clinical trial was going to start...1st Q...we already heard the phase 2b was going to start 1st Q...so it looks like the first of next year will be great for Nuvilex...
bull
Yes it does keep getting better for Nuvilex and the time line is getting closer ....it is already July and the phase 2b and the pre-clinical trial to start first of next year...you could see recruiting of patients by the end of year...so time line is closer than some seem to think...start of trials is 6 months or so away...
bull
Nuvilex has had a low between .25 and .26... 20 days since 4/16 and has not closed below .25 at all....I see it more of a bottoming...
bull
stock is bottoming out nicely...last 2 days.....buying 84%.....selling 16%....BOTH DAYS....
bull
I think it is...Nuvilex and my other speculative stocks have chart patterns like any other stock...I think the people who say techs don't work with small stocks are dead wrong...they do because of all the traders that play with a stock like Nuvilex at this pps...they are the ones following the techs the most...they are trading by them...up and down...
bull
Clinical trials for pain and ascites with TD2 to start 1st Quarter next year...
bull
SNNLive - Nuvilex, Inc.
also the trix is starting to move up finally on the Nuvilex chart....along with inverted hammer yesterday and the MACD rising as the pps falling....all reversal signals...
keep
DD has been done by us on Nuvilex...we know why we own Nuvilex and have patience to wait it out...don't get caught up in that...it is not about Dr. Hoff...
bull
Chart update for Nuvilex
we have a very strong inverted hammer today...let's see if we get our reversal tomorrow...
we also have an uptrend on our MACD since 5/27 at the same time we have a downtrend on the pps...also signals a reversal...
bull
In this Nuvilex article I don't read anything that states untruth...so spam or not...it is in the eye of the beholder and I don't behold it because I don't allow spam...
bull
Meet the Austrianova Thailand team at BIO USA from June 23-26 in San Diego, California.
bul
you can wait all you want to and pay the price...we longs who have foresight chose to get in on the ground floor...trust me that is how I have made a lot of money...by recognizing a stock that the fundamentals are there and all I have to do is have patience and wait...and I have found many...but not like Nuvilex at this pps...going into late stage cancer trials...
but I do think most investors on Ihub are smart enough to handle their own money and do their own DD and invest where they see the lowest risk to reward...
and just my opinion...Nuvilex will make a lot of money for a lot of people...especially the ones who were smart enough to get in now on the bottom floor...
I bought a lot of stocks after the crash that I knew would make me a lot of money...and they did...so that profit goes into stocks like Nuvilex for me...with no regret at all...so all the negative posting does not bother me one bit...I KNOW WHAT I OWN....
good luck to you...
bull
post the article on Nuvilex...
bull
Please don't belittle longs on this mb...we have done our DD on Nuvilex and invested with conviction...to tell someone else what to do with their retirement and investment money is just wrong..
bull
So you are saying no one should invest in a small bio on the cusp of getting an approval going into phase 2b trials...because they are going for approval after the 2b trial...not a large phase 3...so you are saying not to invest...well I think you should take your own advice...I advise no one else to do that...have you ever been invested in small bio's before...
bull